1. VIEW-hub Report: Global Vaccine Introduction and Implementation
IVAC VIEW-hub Global Vaccine Introduction and Implementation Report
June 2017
March 2016
Johns Hopkins Bloomberg School of Public Health
International Vaccine Access Center (IVAC)
Developed from information in the VIEW-hub database/platform
For other VIEW-hub-related inquiries, please contact Kirthini Muralidharan at

2. Historical PCV vs. Rotavirus Vaccine Introduction, by Income Group
Note: Limited projections are available for high income countries.
Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2017.

3. Historical PCV Introduction by Income Group
Note: Limited projections are available for high, upper-middle, and lower-middle income countries
Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2017.

4. Historical Rotavirus Vaccine Introduction by Income Group
Note: Limited projections are available for high, upper-middle, and lower-middle income countries
Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2017.

5. Historical IPV Introduction by Income Group
Note: Limited projections are available for high, upper-middle, and lower-middle income countries
Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2017.

6. Global Introduction Status of Hib Vaccine
REGIONAL/PHASED INTRODUCTIONS:
-Belarus
Introduced – National (190)
Introduced – Subnational (1)
Introduced – Risk Program (1)
Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2017.

7. Global PCV Introduction Status by Year
Target: 194 countries
Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2017.

8. Global PCV Introduction Status
Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2017.

9. Global Introduction Status of PCV
Introduced – National (133)
Introduced – Subnational (5)
Introduced – Risk Program (3)
Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2017.

10. PCV – Current Product Mauritius’s PCV product unknown.
PCV10 and PCV13 (8)
Gavi countries
Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2017.

11. PCV – Current Dosing Schedule
Mauritius’s PCV dosing schedule unknown.
2+1 (57)
3+0 (59)
3+1 (23)
2+1 and 3+1 (1)
Gavi countries
Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2017.

12. PCV– Number of Citations- Impact Studies1
2-9
10+
Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, March 2016.

13. Global Coverage and Access to PCV
Coverage = # of surviving infants covered by DTP3 vaccine in countries that have introduced PCV
Access = # of surviving infants that live in countries that have introduced PCV
Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2017.

14. Gavi PCV Introduction Status by Year
Target: 73 countries
Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2017.

15. Gavi PCV Introduction Status
Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2017.

16. Gavi Countries’ Introduction Status of PCV
Introduced – Phased: Nigeria
Introduced – National (56)
Introduced – Subnational (2)
Not Introduced (15)
Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2017.

17. Coverage and Access to PCV in Gavi Countries
Coverage = # of surviving infants covered by DTP3 vaccine in Gavi countries that have introduced PCV
Access = # of surviving infants that live in Gavi countries that have introduced PCV
Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2017.

18. Global Rotavirus Vaccine Introduction Status by Year
Target: 194 countries
Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2017.

19. Global Rotavirus Vaccine Introduction Status
Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2017.

20. Global Introduction Status of Rotavirus Vaccine
Subnational Intros: Canada, India, Italy, Mali, Philippines, Sweden, Thailand
Introduced – National (85)
Introduced – Subnational (7)
Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2017.

21. Rotavirus Vaccine – Current Product*
RV1 (64)
RV1 - Rotavac (1)
RV5 (19)
RV1 and RV5 (8)
India is using Rotavac, a monovalent rotavirus vaccine. The rest of the RV1-using countries are using Rotarix (by GSK).
Gavi countries
India is using a domestically manufactured RV1 (Rotavac, Bharat Vaccines). *
Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2017.

22. Rotavirus Vaccine – Current Dosing Schedule
Mauritius’s rota dosing schedule unknown.
2+0 (64)
3+0 (20)
2+0 and 3+0 (8)
Gavi countries
Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2017.

23. RV– Number of Citations- Impact Studies
These include countries that are using and evaluating PCV, and countries that have yet to introduce but are modeling/projecting economic impact.
4/74 countries shown here are countries that have not yet introduced PCV, but are conducting modeled economic impact studies.
These 4 countries are:
China
Croatia
Malaysia
Somalia 1
2-9
10+
Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, March 2016.

24. Global Coverage and Access to Rotavirus Vaccine
Coverage = # of surviving infants covered by DTP3 vaccine in countries that have introduced Rota vaccine
Access = # of surviving infants that live in countries that have introduced Rota vaccine
Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2017.

25. Gavi Rotavirus Vaccine Introduction Status by Year
Target: 73 countries
Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2017.

26. Gavi Rotavirus Vaccine Introduction Status
Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2017.

27. Gavi Countries’ Introduction Status of Rotavirus Vaccine
Subnational:
-Pakistan
-India
Introduced – National (41)
Introduced – Subnational (2)
Not Introduced (30)
Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2017.

28. Coverage and Access to Rotavirus Vaccine in Gavi Countries
Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2017.

29. Global IPV Introduction Status by Year
Target: 194 countries
Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2017.

30. Global IPV Introduction Status
Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2017.

31. Global Introduction Status of IPV
Subnational intros: China, Congo, Haiti, India, Philippines, Somalia
Introduced – National (169)
Introduced – Subnational (5)
Countries using IPV without OPV (49)
Note: All other IPV-using countries are also using OPV in their national schedule.
Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2017.

32. IPV – Current Product IPV product unknown for Singapore and Venezuela
IPV (Stand alone) (102)
Combination vaccine (54)
Multiple formulations (16)
Product unknown (2)
Gavi countries
Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2017.

33. IPV– Current Dosing Schedule
1+0 (89)
2+0 (14)
2+1 (11)
3+0 and/or 3+1 (60)
Gavi countries
Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2017.

34. Global Coverage and Access to IPV
Coverage = # of surviving infants covered by DTP3 vaccine in countries that have introduced Rota vaccine
Access = # of surviving infants that live in countries that have introduced Rota vaccine
Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2017.

35. Gavi IPV Introduction Status by Year
Target: 73 countries
Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2017.

36. Gavi IPV Introduction Status
Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2017.

37. Gavi Countries’ Introduction Status of IPV
Subnational intros: Congo, Haiti, India, Somalia
Introduced – National (52)
Introduced – Subnational (3)
Not Introduced (18)
Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2017.

38. Coverage and Access to IPV in Gavi Countries
Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2017.

39. Acknowledgements and Notes
This report is developed by the International Vaccine Access Center (IVAC) at the Johns Hopkins Bloomberg School of Public Health, with support from Gavi, the Bill & Melinda Gates Foundation, and The Task Force for Global Health.
Please note that all forecasted introductions in this report rest on assumptions and may vary. Planned vaccine introduction dates do not imply an obligation by Gavi to support coverage.
Definitions and sources are available in VIEW-hub at
The most current VIEW-hub Report and matching slides can be found at:
For any VIEW-hub-related inquiries, please Kirthini Muralidharan at